Home » Newsletters » BioWorld Science

BioWorld Science

April 22, 2004

View Archived Issues

New data on AVP-893, a prototype of a novel class of antitumor agents from Avanir

Microtubule stabilizing agent potentiates anticancer activity in vitro

Significant prostate function improvements induced by an isoflavone red clover extract

Effective prevention of CINV with palonosetron before cisplatin-based chemotherapy

Therapeutic benefits of rosiglitazone in women with polycystic ovary syndrome

Improved safety profile of pegylated liposomal doxorubicin in metastatic breast cancer

R&D highlights from the 3rd Annual Global Biotech Forum for Investing & Partnering: BioVex

R&D highlights from the 3rd Annual Global Biotech Forum for Investing & Partnering: Concurrent

R&D highlights from the 3rd Annual Global Biotech Forum for Investing & Partnering: Cytopia

PAI-1 inhibitors designed and synthesized at Wyeth

Pyridine acetic acids developed as potent, orally active and selective aldose reductase inhibitors

Janssen claims new alphav integrin inhibitors and their use in cancer, osteoporosis, etc.

Three series of telomerase inhibitors described by researchers at Mitsui Chemicals

De Novo presents two series of beta-secretase inhibitors and their use in AD therapy

Novel proline-based antibacterial agents in early development at Dainippon

Dual PPARalpha/PPARgamma agonists designed at Roche

AstraZeneca patent covers dual NK1 antagonists/5-HT reuptake inhibitors and their use

PEDESTAL trial evaluates alagebrium for diastolic dysfunction

IR-103 shows HIV-1 specific immunogenicity in mouse model

Alovudine enters dose-finding phase IIa study in multiresistant HIV

Roche and Isotechnika restructure ISA-247 collaboration agreement

Apidra receives FDA approval

Private placement financing ensures progress of AEOL-10150 into clinic

Orphan medicinal product status for CA4P for anaplastic thyroid cancer

CT-2106 enters phase I/II trial for colorectal cancer

New preclinical data reported for MPC-4505

Phase II trial of MPC-7869 progresses on schedule

Bristol-Myers Squibb receives North American and Asian license for Javlor

Phase III program commences for Xerecept in peritumoral cerebral edema

Genasense available through Expanded Access Program for advanced melanoma

Phase II trial under way for R-112 in allergic rhinitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.